Quick Answer
Evofem Biosciences, Inc. reported Operating Income Loss of -$7.68 million for the year ending 2024.
- Evofem Biosciences, Inc. showed an increase of +57.0% in Operating Income Loss from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$2.48 million | Q2 2014: -$1.98 million | Q3 2014: -$1.87 million | Q1 2015: -$6.64 million | Q2 2015: -$9.20 million | Q3 2015: -$16.98 million | Q1 2016: -$5.78 million | Q2 2016: -$2.52 million | Q3 2016: -$1.87 million | Q1 2017: -$4.91 million | Q2 2017: -$6.36 million | Q3 2017: -$9.07 million | Q1 2018: -$20.99 million | Q2 2018: -$23.24 million | Q3 2018: -$18.43 million | Q1 2019: -$13.63 million | Q2 2019: -$11.94 million | Q3 2019: -$14.30 million | Q1 2020: -$19.24 million | Q2 2020: -$22.37 million | Q3 2020: -$26.16 million | Q1 2021: -$44.87 million | Q2 2021: -$41.14 million | Q3 2021: -$43.37 million | Q1 2022: -$28.93 million | Q2 2022: -$24.42 million | Q3 2022: -$18.72 million | Q1 2023: -$3.58 million | Q2 2023: -$7.34 million | Q3 2023: -$3.55 million | Q1 2024: -$2.84 million | Q2 2024: -$1.39 million | Q3 2024: -$2.44 million | Q1 2025: $327.0 thousand | Q2 2025: -$1.25 million | Q3 2025: $951.0 thousand.
- Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Operating Income Loss has grown by 46.8%.
- Historical annual values: Fiscal year 2024: -$7.68 million | Fiscal year 2023: -$17.85 million | Fiscal year 2022: -$84.12 million | Fiscal year 2021: -$166.80 million | Fiscal year 2020: -$103.62 million | Fiscal year 2019: -$52.74 million | Fiscal year 2018: -$77.64 million | Fiscal year 2017: -$35.69 million | Fiscal year 2016: -$12.04 million | Fiscal year 2015: -$42.05 million | Fiscal year 2014: -$9.59 million | Fiscal year 2013: -$14.42 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: